复方甘草酸苷改善慢性乙型肝炎患者肝脏炎症的机制研究

被引:16
作者
高学松 [1 ]
高丽丽 [2 ,3 ]
芦红萍 [2 ,3 ]
刘顺爱 [2 ,3 ]
曹金凤 [2 ,3 ]
段雪飞 [1 ]
成军 [2 ,3 ]
机构
[1] 首都医科大学附属北京地坛医院综合科
[2] 首都医科大学附属北京地坛医院传染病研究所
[3] 首都医科大学附属北京地坛医院新发突发传染病研究北京市重点实验室
关键词
肝炎,乙型; 复方甘草酸苷; 单核细胞趋化蛋白2; 上皮来源的中性粒细胞活化肽-78;
D O I
暂无
中图分类号
R512.62 [];
学科分类号
摘要
目的研究复方甘草酸苷改善慢性乙型肝炎患者肝脏炎症的机制。方法将21例慢性乙型肝炎患者分为试验组(10例)与对照组(11例),试验组患者给予复方甘草酸苷200 mg入液静脉输注,同时给予苦参素注射液、还原型谷胱甘肽和多烯磷脂酰胆碱注射液保肝,恩替卡韦抗病毒治疗;对照组患者除不使用复方甘草酸苷外与治疗组治疗相同,疗程均为2周。分别在治疗前后检测患者肝功能指标及多个细胞因子水平。结果两组患者肝功能均有好转,试验组ALT水平[(103.4±80.4)U/L]下降显著(t=6.162,P=0.000);MCP-2治疗后[(40.25±14.51)pg/ml]较治疗前显著下降(t=2.381,P=0.041);ENA-78治疗后较治疗前升高(t=-3.561,P=0.006)。试验组和对照组IL-16、6Ckine、TPO、SCF、TSLP、IL-33、IL-20、IL-21、IL-23、IL-28α、TRAIL和SDF-1α+β治疗前后差异均无统计学意义。试验组和对照组IL-18治疗前后均有所下降。结论复方甘草酸苷可显著改善肝脏炎症,抗炎的机制可能与抑制炎症因子MCP-2,活化ENA-78有关。
引用
收藏
页码:490 / 493
页数:4
相关论文
共 10 条
[1]
Glycyrrhizic acid inhibits apoptosis and fibrosis in carbontetrachloride-induced rat liver injury[J] Bo Liang;Xiao-Ling Guo;Jing Jin;Yong-Chun Ma;Zheng-Quan Feng; World Journal of Gastroenterology 2015,
[2]
恩替卡韦联合复方甘草酸苷治疗代偿期活动性乙型肝炎肝硬化患者的临床研究 [J].
张耀武 .
中国肝脏病杂志(电子版), 2013, 5 (04) :37-41
[3]
肝移植急性肺损伤患者围手术期血浆Eotaxin和MCP-2变化及意义 [J].
沈宁 ;
王艳玲 ;
郭娜 ;
黑子清 .
中山大学学报(医学科学版), 2011, 32 (05) :612-615
[4]
IL‐18 ; TNF ; and IFN‐γ alleles and genotypes are associated with susceptibility to chronic hepatitis B infection and severity of liver injury[J] Sandro da Costa Ferreira;Silvana Gama Florêncio Chachá;Fernanda Fernandes Souza;Andreza Corrêa Teixeira;Rodrigo de Carvalho Santana;Neifi Hassan Saloun Deghaide;Sandra Rodrigues;Leonardo Arduíno Marano;Celso Teixeira Mendes‐Junior;Sérgio Zucoloto;Eduardo Ant?nio Donadi;Ana de Lourdes Candolo Martinelli J. Med. Virol. 2015,
[5]
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV / HCV co‐infected patients[J] M. K. Jain;B. Adams‐Huet;D. Terekhova;L. E. Kushner;R. Bedimo;X. Li;M. Holodniy J Viral Hepat 2015,
[6]
CXCR2/CXCL5 axis contributes to epithelial–mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling[J] Shao-Lai Zhou;Zheng-Jun Zhou;Zhi-Qiang Hu;Xun Li;Xiao-Wu Huang;Zheng Wang;Jia Fan;Zhi Dai;Jian Zhou Cancer Letters 2015,
[7]
Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review[J] Jian-yuan Li;Hong-yan Cao;Ping Liu;Gen-hong Cheng;Ming-yu Sun;Kota V. Ramana BioMed Research International 2014,
[8]
Human cytomegalovirus latency alters the cellular secretome; inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function[J] Gavin M. Mason;Emma Poole;J. G. Patrick Sissons;Mark R. Wills;John H. Sinclair Proceedings of the National Academy of Sciences 2012,
[9]
Glycyrrhizic acid and 18β-glycyrrhetinic acid recover glucocorticoid resistance via PI3K-induced AP1; CRE and NFAT activation[J] Tzu-Chien Kao;Chi-Hao Wu;Gow-Chin Yen Phytomedicine 2012,
[10]
Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis[J] Marlene Dominguez;Rosa Miquel;Jordi Colmenero;Montserrat Moreno;Joan–Carles García–Pagán;Jaime Bosch;Vicente Arroyo;Pere Ginès;Juan Caballería;Ramón Bataller Gastroenterology 2009,